Regenerative therapy for patients with congenital heart disease

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Congenital heart disease (CHD) is the most common birth defect, affecting 1 in 100 babies. Among CHDs, single ventricle (SV) physiologies, such as hypoplastic left heart syndrome and tricuspid atresia, are particularly severe conditions that require multiple palliative surgeries, including the Fontan procedure. Although the management strategies for SV patients have markedly improved, the prevalence of ventricular dysfunction continues to increase over time, especially after the Fontan procedure. At present, the final treatment for SV patients who develop heart failure is heart transplantation; however, transplantation is difficult to achieve because of severe donor shortages. Recently, various regenerative therapies for heart failure have been developed that increase cardiomyocytes and restore cardiac function, with promising results in adults. The clinical application of various forms of regenerative medicine for CHD patients with heart failure is highly anticipated, and the latest research in this field is reviewed here. In addition, regenerative therapy is important for children with CHD because of their natural growth. The ideal pediatric cardiovascular device would have the potential to adapt to a child’s growth. Therefore, if a device that increases in size in accordance with the patient’s growth could be developed using regenerative medicine, it would be highly beneficial. This review provides an overview of the available regenerative technologies for CHD patients.

Original languageEnglish
Pages (from-to)29-38
Number of pages10
JournalKeio Journal of Medicine
Volume68
Issue number2
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Heart Diseases
Fontan Procedure
Regenerative Medicine
Heart Failure
Growth
Tricuspid Atresia
Hypoplastic Left Heart Syndrome
Ventricular Dysfunction
Therapeutics
Equipment and Supplies
Heart Transplantation
Palliative Care
Cardiac Myocytes
Transplantation
Tissue Donors
Pediatrics
Technology
Research

Keywords

  • Congenital heart disease
  • Heart failure
  • Regenerative therapy
  • Stem cell

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Regenerative therapy for patients with congenital heart disease. / Kimura, Naritaka.

In: Keio Journal of Medicine, Vol. 68, No. 2, 01.01.2019, p. 29-38.

Research output: Contribution to journalReview article

@article{aa3b67bc2447431db2762928d09f6c90,
title = "Regenerative therapy for patients with congenital heart disease",
abstract = "Congenital heart disease (CHD) is the most common birth defect, affecting 1 in 100 babies. Among CHDs, single ventricle (SV) physiologies, such as hypoplastic left heart syndrome and tricuspid atresia, are particularly severe conditions that require multiple palliative surgeries, including the Fontan procedure. Although the management strategies for SV patients have markedly improved, the prevalence of ventricular dysfunction continues to increase over time, especially after the Fontan procedure. At present, the final treatment for SV patients who develop heart failure is heart transplantation; however, transplantation is difficult to achieve because of severe donor shortages. Recently, various regenerative therapies for heart failure have been developed that increase cardiomyocytes and restore cardiac function, with promising results in adults. The clinical application of various forms of regenerative medicine for CHD patients with heart failure is highly anticipated, and the latest research in this field is reviewed here. In addition, regenerative therapy is important for children with CHD because of their natural growth. The ideal pediatric cardiovascular device would have the potential to adapt to a child’s growth. Therefore, if a device that increases in size in accordance with the patient’s growth could be developed using regenerative medicine, it would be highly beneficial. This review provides an overview of the available regenerative technologies for CHD patients.",
keywords = "Congenital heart disease, Heart failure, Regenerative therapy, Stem cell",
author = "Naritaka Kimura",
year = "2019",
month = "1",
day = "1",
doi = "10.2302/kjm.2018-0002-IR",
language = "English",
volume = "68",
pages = "29--38",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "2",

}

TY - JOUR

T1 - Regenerative therapy for patients with congenital heart disease

AU - Kimura, Naritaka

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Congenital heart disease (CHD) is the most common birth defect, affecting 1 in 100 babies. Among CHDs, single ventricle (SV) physiologies, such as hypoplastic left heart syndrome and tricuspid atresia, are particularly severe conditions that require multiple palliative surgeries, including the Fontan procedure. Although the management strategies for SV patients have markedly improved, the prevalence of ventricular dysfunction continues to increase over time, especially after the Fontan procedure. At present, the final treatment for SV patients who develop heart failure is heart transplantation; however, transplantation is difficult to achieve because of severe donor shortages. Recently, various regenerative therapies for heart failure have been developed that increase cardiomyocytes and restore cardiac function, with promising results in adults. The clinical application of various forms of regenerative medicine for CHD patients with heart failure is highly anticipated, and the latest research in this field is reviewed here. In addition, regenerative therapy is important for children with CHD because of their natural growth. The ideal pediatric cardiovascular device would have the potential to adapt to a child’s growth. Therefore, if a device that increases in size in accordance with the patient’s growth could be developed using regenerative medicine, it would be highly beneficial. This review provides an overview of the available regenerative technologies for CHD patients.

AB - Congenital heart disease (CHD) is the most common birth defect, affecting 1 in 100 babies. Among CHDs, single ventricle (SV) physiologies, such as hypoplastic left heart syndrome and tricuspid atresia, are particularly severe conditions that require multiple palliative surgeries, including the Fontan procedure. Although the management strategies for SV patients have markedly improved, the prevalence of ventricular dysfunction continues to increase over time, especially after the Fontan procedure. At present, the final treatment for SV patients who develop heart failure is heart transplantation; however, transplantation is difficult to achieve because of severe donor shortages. Recently, various regenerative therapies for heart failure have been developed that increase cardiomyocytes and restore cardiac function, with promising results in adults. The clinical application of various forms of regenerative medicine for CHD patients with heart failure is highly anticipated, and the latest research in this field is reviewed here. In addition, regenerative therapy is important for children with CHD because of their natural growth. The ideal pediatric cardiovascular device would have the potential to adapt to a child’s growth. Therefore, if a device that increases in size in accordance with the patient’s growth could be developed using regenerative medicine, it would be highly beneficial. This review provides an overview of the available regenerative technologies for CHD patients.

KW - Congenital heart disease

KW - Heart failure

KW - Regenerative therapy

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=85068923892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068923892&partnerID=8YFLogxK

U2 - 10.2302/kjm.2018-0002-IR

DO - 10.2302/kjm.2018-0002-IR

M3 - Review article

C2 - 29925723

AN - SCOPUS:85068923892

VL - 68

SP - 29

EP - 38

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 2

ER -